Two Regimens of IVIG in the Treatment of Newly Diagnosed ITP in Children
Recruiting
Phase 4
Interventional Study
Newly Diagnosed Immune Thrombocytopenia in Children, First Line Treatment
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 29 Days – 14
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 580 (estimated)
- Sponsor
- Fujian Medical University Union Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
To compare the efficacy of two different dosage regimens of intravenous immune globulin (IVIG) in the treatment of children with newly diagnosed immune thrombocytopenia, and to reduce related adverse reactions and economic burdens on the premise of ensuring the remission rate
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:Subjects enrolled in this study must meet all of the following criteria:
1. Meet the diagnostic criteria of ITP and be diagnosed for the first time without treatment
2. Age \> 28 days and ≤ 14 years old
3. PLT\<20×109/L
4. Have signed the informed consent
Exclusion Criteria:Anyo…
Contacts